


ALERTA Nº 19/2018

PROGRAMME	HORIZON 2020 (2014-2020)
CALL	<p style="text-align: center;">Health</p> <p style="text-align: center;">SC1-DTH-10-2019-2020: Digital health and care services (Pre-Commercial Procurement)</p>
FUNDING BODY	<ul style="list-style-type: none"> European Commission
CALL FOCUS	<ul style="list-style-type: none"> To to network, lead and facilitate health systems research, innovation and digitisation in view of addressing key areas of interventions in health and care services including health promotion and disease prevention
ELIGIBLE APPLICANTS	<ul style="list-style-type: none"> At least three legal entities. Each of the three must be established in a different EU Member State or Horizon 2020 associated country. All three legal entities must be independent of each other. Furthermore, there must be <u>a minimum of two legal entities which are 'public procurers'</u> from two different EU Member States or Horizon 2020 associated countries. Both legal entities must be independent of each other.
TOPIC DESCRIPTION	<ul style="list-style-type: none"> SC1-DTH-10-2019-2020: Digital health and care services <p>Scope: Support the health and care service provider to procure the development, testing and implementation of digital services and communication concepts that can facilitate the transition to integrated care models across health and social services and country-specific cross-institutional set-ups, including decentralised procurement environments and collaboration across institutions. Key challenges that could be addressed are patient empowerment, self-management, patient safety, patient involvement, chronic disease management, diagnosing, home-care logistics, hospital logistics, skills and independent living. These challenges could be addressed by applicable ICT domains e.g., telemedicine, mHealth, IoT, shared open source IT-based platforms, etc. as will be defined in the market consultation process. This should result in early adoption and demonstration of the potential for scaling-up the services and positive impact with evidence of appropriate incentives of various actors.</p> <p>Expected Impact:</p> <ul style="list-style-type: none"> Established path to innovation, evidence of benefits of disruptive technologies that can support the development of sustainable business models, improved user and market engagement, strengthened procurement community, evidence of healthy innovation ecosystem including researchers, users, eHealth and other solution providers and procurers. Evidence in key performance areas i.e., quality in health and care, sustainability of the delivery system and economic value. Increased opportunities for solution uptake across wider international procurement markets by aiming at interoperable solutions that are validated through field testing by participating procurers in multiple countries across Europe and contribution to standardisation where relevant. <p>Indicative request from the EU: around €5-6M</p> <p>Type of Action: Pre – Commercial Procurement</p>
INSTRUMENT FUNDING LEVEL	<ul style="list-style-type: none"> The funding rate for Pre-Commercial Procurement (PCP) actions is limited to 90% of the total eligible costs (PCP is procurement of R&D services) to leverage co-financing from the procurers.

ELIGIBLE COSTS	<ul style="list-style-type: none"> • Personnel cost. • Other direct cost: travel and subsistence; equipment, informatics, consumables. • Subcontracting. • Indirect cost (25% total direct cost, except subcontracting).
REMARKS	<ul style="list-style-type: none"> • Information on the outcome of the evaluation: Maximum 5 months from the final date for submission. • Indicative date for the signing of grant agreements: Maximum 8 months from the final date for submission.
INDICATIVE BUDGET	<ul style="list-style-type: none"> • Total budget € million → 22.00
DEADLINE	<ul style="list-style-type: none"> • 14/11/2018
MÁS INFORMACIÓN	<ul style="list-style-type: none"> • http://ec.europa.eu/research/participants/portal/desktop/en/opportunities/index.html
DISTRIBUCIÓN	<ul style="list-style-type: none"> • Socios numerarios de la Asociación IBV y socios corporativos de la Asociación CVIDA • Actualizado: 12/09/2018
	




El Instituto de Biomecánica de Valencia pone a disposición de los socios un servicio de alertas de ayudas y subvenciones públicas de apoyo a la I+D.

El objetivo de este servicio es informar a las empresas, a través del envío de fichas-resumen, de las ayudas y subvenciones convocadas por la Administración Autonómica Valenciana, por la Administración Central y por la Unión Europea, con la intención de identificar posibles vías de financiación de sus proyectos empresariales.


Estas fichas contienen información sobre destinatarios, condiciones y plazos para concurrir a las convocatorias y son enviadas a los socios, de forma temprana, una vez salen publicadas en los boletines oficiales correspondientes.



Una manera de hacer Europa



- **Public procurement (PP)** is the process whereby public authorities - including all levels of government and public agencies - buy goods and services or commission work. This enables faster modernization of public services while opening market opportunities for companies in Europe. **Horizon 2020** provides EU funding to promote PP through different types of support for procurers:
- **Coordination and Support actions (CSA)** support coordination and networking activities for groups of procurers to investigate the feasibility and/or prepare the ground for concrete future innovation procurements.
- **Pre-commercial procurement (PCP) or Public procurement of innovation (PPI) Cofund actions** co-finance both the procurement cost for groups of procurers to buy together the research, development and validation (PCP) or deployment (PPI) of innovative solutions as well as coordination and networking costs to prepare, manage and follow up such procurements.



'Pre-commercial procurement (PCP)' means procurement of research and development services involving risk-benefit sharing under market conditions, and competitive development in phases, where there is a clear separation of the research and development services procured from the deployment of commercial volumes of end-products.

'Public procurement of innovative solutions (PPI)' means procurement where contracting authorities act as a launch customer for innovative goods or services which are not yet available on a large-scale commercial basis, and may include conformance testing.

PROGRAMME	<p style="text-align: center;">H2020 (2014-2020)</p> <p style="text-align: center;">PRE-COMMERCIAL PROCUREMENT, PCP ACTIONS</p>
FUNDING BODY	<ul style="list-style-type: none"> European Commission.
DESCRIPTION	<ul style="list-style-type: none"> PCP actions aim to encourage public procurement of research, development and validation of new solutions that can bring significant quality and efficiency improvements in areas of public interest, whilst opening market opportunities for industry and researchers active in Europe. The PCP must address one concrete procurement need that is identified as a common challenge. This action provides EU funding for a group of procurers ('buyers group') to undertake together one joint PCP procurement, so that there is one joint call for tender, one joint evaluation of offers, and a lead procurer (coordinator) awarding the R&D service contracts in the name and on behalf of the buyers group.
ELIGIBLE PARTICIPANTS	<ul style="list-style-type: none"> The buyers group must contain <u>minimum two legal entities, which are public procurers</u> that are established in two different Member States or associated countries. Both legal entities must be independent of each other. <u>Other entities</u> (e.g. end-users, certification bodies, private/NGO procurers that provide services of public interest and share the same procurement need) whose participation is well justified may participate in additional activities that clearly add value to the action and support the preparation and execution of the PCP or embed the PCP into a wider set of demand side activities. 'Sole participants' must indicate which of its 'members' are the procurers contributing to the budget of the proposed joint procurement that satisfy the participation requirements and which are the respective procurement budgets of each of these members that are at the disposal for carrying out the procurement. A sole participant acting as buyers group must have a mandate based on a well-defined procurement need and budget from its procurers to act on their behalf.
ACTIVITIES	<p>A) Preparation and publication of the open market consultation and call for tender</p> <ul style="list-style-type: none"> An open dialogue with potential tenderers and end-users must be held to broach the views of the market about the intended R&D scope. The results of this open market consultation must be duly taken into account to fine-tune the tender specifications, so that the gap between state-of-the-art industry development and the procurement needs justifies the need to procure R&D services. The prior information notice for the open market consultation and the PCP contract notice must be promoted and advertised widely using in particular also Horizon 2020 Internet sites and National Contact Points. The PCP call for tender must remain open for the submission of tenders for at least 60 days. <p>B) Tender documentation and procurement procedure</p> <ul style="list-style-type: none"> The PCP contract notice must contain information on the intended number of R&D providers that will be selected (minimum three) to start the PCP, the number of PCP phases and the expected duration and budget for each PCP phase. The PCP procurement must cover the full PCP life cycle of solution design, prototyping, and original development including testing of a limited volume of test series products/services. Each of the three PCP phases can be split up into further phases if appropriate. <u>Evaluation</u> of the tenders must be based on <u>best value for money</u> criteria, not just lowest price. <u>Potential providers of solutions sought for by a PCP cannot be beneficiaries in an action during which this PCP is planned or undertaken.</u> In PCP, procurers do not reserve the R&D results exclusively for their own use. An R&D provider generating results in PCP must own the attached IPRs. The procurers must enjoy royalty-free access rights to use the R&D results for their own use.

PROGRAMME	<p style="text-align: center;">H2020 (2014-2020)</p> <p style="text-align: center;">PRE-COMMERCIAL PROCUREMENT, PCP ACTIONS</p>
ELIGIBLE COSTS	<ul style="list-style-type: none"> • The price of the R&D services procured via the joint PCP and the costs of the coordination and networking activities, and may include in-kind contributions of third parties linked to grant beneficiaries. • Indirect costs are calculated as a flat rate of 25% of direct eligible costs, excluding direct eligible costs for subcontracting (e.g the price of the PCP procurement) and costs of resources made available by third parties which are not used on the premises of the beneficiary (e.g test equipment).
FUNDING RATE	<ul style="list-style-type: none"> • Work Programme 2018-2020. The funding rate is limited to 90% of eligible costs.